Amir Iravani

Associate Professor

University of Washington

United States

Research Interests

Explore related searches

Professors in United States Professors in Medical Imaging Medical Imaging professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Amir Iravani is an Associate Professor at the University of Washington in the United States. His research focuses on the application of imaging techniques, particularly 18 F-FDG PET/CT, in assessing immune responses to therapies in cancer, including melanoma and prostate cancer. Recent publications highlight his work on thyroid activity associated with immune checkpoint inhibition, clinical outcomes in metastatic melanoma, and advancements in theranostics.

Articles (11)

Year:

2023

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Kortnye Smith

Peter MacCallum Cancer Institute

AUSTRALIA

View details

Justin Ferdinandus

University Hospital Bonn

GERMANY

View details

Shahneen Sandhu

AUSTRALIA

View details

Nirupa Sachithanandan

University of Melbourne

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Amir Iravani

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis

<sup>18</sup>F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

<sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond

A Malignant Neoplasm From the Jejunum With a MALAT1-GLI1 Fusion and 26-Year Survival History

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Imaging the cancer immune environment and its response to pharmacologic intervention, Part 1: The role of <sup>18</sup>F-FDG PET/CT

Imaging the cancer immune environment and its response to pharmacologic intervention, part 2: The role of novel PET agents

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Editorial Comment

Collaborators (4)

Kortnye Smith

Justin Ferdinandus

Shahneen Sandhu

Nirupa Sachithanandan

Make your next move.